Skip to content
  • Home
  • World News
  • Business
  • Aviation
195 news

195News

All the news that's fit to print

  • Home
  • World News
  • Business
  • Aviation
  • Toggle search form
  • Day 388: war diaries w/Former Advisor to Ukraine President, Intel Officer  @arestovych  & #Feygin
    Day 388: war diaries w/Former Advisor to Ukraine President, Intel Officer @arestovych & #Feygin World News
  • Питер Крон: “Как Превзойти Созданные Страдания и Обнаружить Свою Непреходящую Ценность?”  ч.1 (рус)
    Питер Крон: “Как Превзойти Созданные Страдания и Обнаружить Свою Непреходящую Ценность?” ч.1 (рус) World News
  • New Compensation Report Reveals How Salaries and Bonuses Are Set for Corporate Innovation and Strategy Leaders
    New Compensation Report Reveals How Salaries and Bonuses Are Set for Corporate Innovation and Strategy Leaders Business
  • Engineering Services Market Size Expected To Reach 16 Billion By 2027
    Engineering Services Market Size Expected To Reach $1316 Billion By 2027 World News
  • Global Opportunity Analysis and Industry Forecast, 2023-2032
    Global Opportunity Analysis and Industry Forecast, 2023-2032 Business
  • War Day 240: war diaries w/Advisor to Ukraine President, Intel Officer @arestovych & #Feygin
    War Day 240: war diaries w/Advisor to Ukraine President, Intel Officer @arestovych & #Feygin World News
  • Anyword Recognized as Leader in AI Copywriting Assistance in G2 Fall 2022 Report
    Anyword Recognized as Leader in AI Copywriting Assistance in G2 Fall 2022 Report Business
  • Naturetec Innovates with Ultrasound in Extract Production
    Naturetec Innovates with Ultrasound in Extract Production Business
Advancing Claudin-1 Expression Research with Cutting-edge Technologies

Advancing Claudin-1 Expression Research with Cutting-edge Technologies

Posted on September 30, 2023 By NewsEditor

KYAN Technologies,Alentis Therapeutics,and CELLphenomics Join Forces Combining Cutting-edge Optim.AI™ and PD3D® Models to Advance Claudin-1 Expression Research

SINGAPORE, SINGAPORE, September 30, 2023 /EINPresswire.com/ — KYAN Technologies, a vanguard combinatory drug development solutions provider, is thrilled to announce a strategic partnership with Alentis Therapeutics, a clinical-stage biopharmaceutical company developing breakthrough treatments for Claudin-1 positive tumours and organ fibrosis. This partnership aims to accelerate research into Claudin-1 expression using innovative patient-derived 3D (PD3D®) cell culture models provided by CELLPhenomics.

Claudin-1 (CLDN1) is a member of the tight junction protein family. In many solid tumours and during organ fibrosis CLDN1 is overexpressed and exposed outside of tight junctions, where it plays a key role in disease pathogenesis. Alentis is rapidly advancing a clinical pipeline of antibodies specifically targeting exposed CLDN1, unlocking a new mode of action to treat cancer and reverse fibrosis.

Through this collaboration, all three organizations will leverage their respective expertise and resources to advance Claudin-1 expression research to new heights. KYAN Technologies will bring its cutting-edge Optim.AI™ platform, a revolutionary technology that employs small data AI and experimentally derived datasets. Optim.AI™ solves large and complex search spaces to identify and rank combination treatments across the spectrum of biological models. Alentis Therapeutics will contribute its extensive experience in disease research and drug development, while CELLPhenomics, a renowned provider of complex patient-derived cell culture models will provide hyper-characterized models tailored specifically for CLDN1 expression studies and subsequent compound screening.

This exciting research partnership enables more precise and detailed insights into the role of CLDN1 in cancer, paving the way for novel therapeutic approaches.

Mr Hugo Saavedra, CEO of KYAN Technologies, expressed enthusiasm about the partnership, saying, “We are thrilled to have a strategic alliance with CELLphenomics and work together to support Alentis as we all strive to pave the way for better cancer care. This is an opportunity to leverage our Optim.AI platform in a powerful union to accelerate the development of novel therapies that can provide meaningful benefits to patients suffering from cancer and fibrotic diseases.”

Alberto Toso, SVP Head of Oncology at Alentis Therapeutics, added, “We are pleased to partner with KYAN Technologies and CELLphenomics in our pursuit of developing novel Claudin-1 targeting therapies to treat cancer. We eagerly await the results from the experiments using state-of-the-art patient-derived cell models and the AI platform to inform our development efforts.”

Dr. Christoph Reinhard, CSO of CELLphenomics added, “It is critical to have disease-relevant models such as our proprietary PD3D® models for an ambitious project like this one. Our combined technologies yield more than a half million possible results per experiment. You simply cannot unlock the power of AI with the classic existing models such as generic cell lines or PDX when it comes to clinical utility.”

The scientific and medical communities can anticipate groundbreaking discoveries and novel insights into CLDN1, which represents a significant step forward in the pursuit of improved treatments to benefit patients with CLDN1+ tumours worldwide.

About KYAN Technologies:

KYAN Technologies, a pioneering leader in the field of functional precision medicine. Our company is dedicated to revolutionizing cancer care by leveraging cutting-edge technology and expertise.

KYAN has developed Optim.AI, a state-of-the-art platform solution for clinical decision support and efficient drug development. This powerful tool empowers healthcare providers and scientists by providing them with critical insights to make informed clinical and research decisions.

Our core mission is to bridge the existing gap in cancer care, and we achieve this through our unique specialization in integrating small data AI and biological experiments. Through our proprietary platform, we offer a truly personalized solution that transforms the identification of optimal outcomes from vast drug-dose combinations, to improve the development and delivery of therapies to patients.

In addition to supporting healthcare providers and patients, KYAN is committed to aiding more efficient and accelerated drug development. From the development of novel biopharmaceutical assets to repurposing and expanding the use of drugs, KYAN’s aim is to help bring better treatment options to as many patients as possible.

For more information, visit https://kyantechnologies.com/

About Alentis Therapeutics:

Alentis Therapeutics, the CLDN1 company, is a clinical-stage biotech developing breakthrough treatments for CLDN1+ tumours and organ fibrosis. Alentis is the leading company pioneering a novel approach to modify and reverse the course of disease by targeting CLDN1, a previously unexploited target that plays a key role in the pathology of cancer and fibrotic disease.

Alentis was founded in 2019 based on ground-breaking research in the laboratory of Prof. Thomas Baumert, MD at the University of Strasbourg and the French National Institute of Health (Inserm). Alentis is headquartered in pharma-biotech hub Basel, Switzerland with an R&D subsidiary in Strasbourg, France and clinical operations in the US.

For more information, visit

About CELLPhenomics:

CELLphenomics GmbH is a German biotech company founded in 2014.

The core competence of cellphenomics is the establishment and cultivation of complex patient-derived cell culture models (PD3D®) from various solid tumor tissues and their application for research and high-throughput as well as personalized toxicity testing. PD3D® models robustly recapitulate the biological properties of the donor tissue, making them the ideal tool to systematically study the characteristics that make up the tumor phenotype. It is the relationship between phenotype and genotype that enables researchers to understand and study treatment sensitivity and resistance.

CELLphenomics’ proprietary precision medicine PD3D® platform offers high-throughput efficacy testing, drug combination screening, toxicity profiling, target validation, drug sensitivity correlation with clinical response, and biomarker identification. The continuously growing biobank comprises more than 450 organoid models from more than 20 tumor entities and is complemented by clinical and molecular data to support different research interests.

For more information, visit https://www.cellphenomics.com/

For media inquiries, please contact:

Sudha Sruthi, Corporate Development, KYAN Technologies

ssruthi@kyantechnologies.com

Melanie Alperstaedt, Corporate Communications, CellPhenomics

melanie.alperstaedt@cellphenomics.com

Sariette Witte, Head of Communications, Alentis Therapeutics

sariette.witte@alentis.ch

Sudha Sruthi
KYAN Technologies Pte Ltd
+1 780-273-4848
email us here
Visit us on social media:
LinkedIn

Advancing Claudin-1 Expression Research with Cutting-edge Technologies

You just read:

News Provided By

September 30, 2023, 00:08 GMT


EIN Presswire’s priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content.
As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone’s Internet News Presswire™,
tries to define some of the boundaries that are reasonable in today’s world. Please see our
Editorial Guidelines
for more information.

Article originally published on www.einpresswire.com as Advancing Claudin-1 Expression Research with Cutting-edge Technologies

World News

Post navigation

Previous Post: War Day 132: war diaries w/Advisor to Ukraine President, Intel Officer @arestovych & #Feygin
Next Post: FlashIntel Spearheads Remarkable Sales Transformation for Lark

Related Posts

  • TELF AG Reports that Livista Energy Europe is set to Build Low-Carbon Lithium Refinery in Germany
    TELF AG Reports that Livista Energy Europe is set to Build Low-Carbon Lithium Refinery in Germany World News
  • Vapor Technology Association Statement on Critical Reagan-Udall Foundation Final Report
    Vapor Technology Association Statement on Critical Reagan-Udall Foundation Final Report World News
  • Secretary Antony J. Blinken and UK Foreign Secretary James Cleverly at a Joint Press Availability
    Secretary Antony J. Blinken and UK Foreign Secretary James Cleverly at a Joint Press Availability World News
  • Collagen Peptide and Gelatin Market Drivers Shaping Future Growth, Revenue .67 Billion by 2030
    Collagen Peptide and Gelatin Market Drivers Shaping Future Growth, Revenue $7.67 Billion by 2030 World News
  • War Day 335: war diaries w/Advisor to Ukraine President, Intel Officer @arestovych & #Feygin
    War Day 335: war diaries w/Advisor to Ukraine President, Intel Officer @arestovych & #Feygin World News
  • Barrows Hotel Enterprises starts offering Sharia Compliant Investments
    Barrows Hotel Enterprises starts offering Sharia Compliant Investments World News
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
« May    
last celebrity gossip
Gossip Stone - celebrity life and gossip

Recent Posts

  • Projected To Reach $3.7Billion By 2029 With An Impressive 9.6% CAGRJune 25, 2025
  • Dunbrook Associates Offers Complimentary Consultations to New ClientsJune 25, 2025
  • Luxury & Beauty With Purpose: A Noble Foundation Elevates Healing Through DesignJune 25, 2025
  • International Solar Alliance to Host Sixth Regional Committee Meeting for Europe & Others Region in BrusselsJune 24, 2025
  • FinlyWealth Revolutionizes Credit Card Comparison in Canada with Data-Driven, Personalized ToolJune 24, 2025
Brand Values Content
VUGA Enterprises - media network PR & Marketing
  • War Day 160: war diaries w/Advisor to Ukraine President, Intel Officer @arestovych  & #Feygin
    War Day 160: war diaries w/Advisor to Ukraine President, Intel Officer @arestovych & #Feygin World News
  • Stenograph® Announces Phoenix on Demand, Allowing Rapid Transcript Creation From Audio Files
    Stenograph® Announces Phoenix on Demand, Allowing Rapid Transcript Creation From Audio Files Business
  • Lyophilized Injectable Drugs Market Size, Share And Growth Analysis For 2024-2033
    Lyophilized Injectable Drugs Market Size, Share And Growth Analysis For 2024-2033 World News
  • “Hand in Hand, Building a Better Community” 2025 International Women’s Day Forum Successfully Held
    “Hand in Hand, Building a Better Community” 2025 International Women’s Day Forum Successfully Held Business
  • No Label Brewing Celebrates IPA Day and Kicks Off Houston Craft Beer Month with Epic Events and Community Support
    No Label Brewing Celebrates IPA Day and Kicks Off Houston Craft Beer Month with Epic Events and Community Support Business
  • Update on Passport Processing Times
    Update on Passport Processing Times World News
  • Review Panel’s Final Report on Organization Designation Authorizations (ODA) for the Design and Production of Airplanes
    Review Panel’s Final Report on Organization Designation Authorizations (ODA) for the Design and Production of Airplanes Aviation
  • Space Logistics Market is Projected to Grow Expeditiously: to Reach USD 19.8 Billion by 2040, Report
    Space Logistics Market is Projected to Grow Expeditiously: to Reach USD 19.8 Billion by 2040, Report Aviation
aerospace company
stem cell clinic in kiev
medical spa in miami
Fashion TV free

Copyright © 2023 195 News. All Rights Reserved by Coolaser | Partner of VUGA Enterprises |  Advertising: Get Published

Powered by .